Double-Targeting CAR-T cells aim to outsmart lymphoma relapse
NCT ID NCT07461831
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial tests a new type of CAR-T cell therapy that targets two proteins (CD19 and CD22) on lymphoma cells, aiming to prevent the cancer from escaping treatment. It involves 100 adults with relapsed or refractory large B-cell lymphoma who have not responded to standard therapies. The main goal is to see how many patients achieve a significant reduction in tumor size within three months.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
CD19/CD22 bispecific CAR-T cells
What this could lead to
If successful, this therapy could offer a more effective treatment option for patients with hard-to-treat large B-cell lymphoma, potentially reducing the chance of relapse.
What could go wrong
This is a single-center, phase 2 trial with 100 participants, so results may not apply broadly. CAR-T therapy carries risks like severe immune reactions and side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LARGE B-CELL LYMPHOMA (LBCL) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Beijing Tongren Hospital, Capital Medical University
Beijing, Beijing Municipality, 100730, China